Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
, and this route of absorption is unaffected in patients with pernicious anemia
Because AOD9604 does not stimulate IGF-1 production and lacks strong GH receptor agonism, it may present a safer alternative for long-term OA treatment [1]
One proposed advantage of AOD-9604 is that it minimally impacts insulin levels compared to full growth hormone
It is classified as a triple incretin receptor agonist, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
US$ 24.17
US$ 29.69
US$ 23.40
US$ 28.75
US$ 25.73
US$ 25.86
